BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24161525)

  • 1. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
    Necchi A; Nicolai N; Mariani L; Lo Vullo S; Giannatempo P; Raggi D; Farè E; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Milani A; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Feb; 12(1):63-69.e1. PubMed ID: 24161525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
    Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
    Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer.
    McKenzie HS; Mead G; Huddart R; White JD; Rustin GJS; Hennig IM; Cozens K; Cross N; Bowers M; Wheater MJ
    Clin Genitourin Cancer; 2018 Dec; 16(6):458-465.e2. PubMed ID: 30115544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
    Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
    Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
    Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C
    Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
    Nicolai N; Necchi A; Gianni L; Piva L; Biasoni D; Torelli T; Stagni S; Milani A; Pizzocaro G; Salvioni R
    BJU Int; 2009 Aug; 104(3):340-6. PubMed ID: 19239440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    Einhorn LH; Brames MJ; Juliar B; Williams SD
    J Clin Oncol; 2007 Feb; 25(5):513-6. PubMed ID: 17290059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
    De Pasquale MD; D'Angelo P; Crocoli A; Boldrini R; Conte M; Bisogno G; Spreafico F; Inserra A; Biasoni D; Dall'Igna P; Siracusa F; Miele E; Terenziani M
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28125. PubMed ID: 31850649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    Mulherin BP; Brames MJ; Einhorn LH
    Am J Clin Oncol; 2015 Aug; 38(4):373-6. PubMed ID: 26214082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
    Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
    Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.
    Shiraishi T; Nakamura T; Mikami K; Takaha N; Kawauchi A; Miki T
    Int J Clin Oncol; 2009 Oct; 14(5):436-41. PubMed ID: 19856053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
    Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
    BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma.
    Hirata T; Hanamoto M; Ogura K; Hayashi N; Takamura K; Edamura K; Ebara S; Saika T
    Acta Med Okayama; 2018 Apr; 72(2):175-179. PubMed ID: 29674766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
    Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
    Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer.
    Li Y; Zhao Y; Gong C; Xie Y; Hu X; Zhang J; Wang L; Zhang S; Cao J; Tao Z; Wang B
    Sci Rep; 2019 Mar; 9(1):3563. PubMed ID: 30837503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
    Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
    Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
    Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
    Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
    Farmakis D; Pectasides M; Pectasides D
    Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
    Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
    Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
    Bokemeyer C; Oechsle K; Honecker F; Mayer F; Hartmann JT; Waller CF; Böhlke I; Kollmannsberger C;
    Ann Oncol; 2008 Mar; 19(3):448-53. PubMed ID: 18006893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.